Humanised monoclonal antibody therapy for rheumatoid arthritis.
Monoclonal antibodies that target T cells have shown some benefit in rheumatoid arthritis although responses have not been long lasting. This is partly due to insufficient therapy consequent upon antibody immunogenicity. Use of humanised antibodies, which are expected to be less foreign to man than...
Auteurs principaux: | Isaacs, J, Watts, R, Hazleman, B, Hale, G, Keogan, M, Cobbold, S, Waldmann, H |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
1992
|
Documents similaires
-
HUMANIZED MONOCLONAL-ANTIBODY THERAPY IN RHEUMATOID-ARTHRITIS
par: Isaacs, J, et autres
Publié: (1992) -
Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
par: Isaacs, J, et autres
Publié: (2004) -
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
par: Isaacs, J, et autres
Publié: (2005) -
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
par: Isaacs, J, et autres
Publié: (2005) -
Humanized monoclonal antibody treatment in rheumatoid arthritis.
par: Kyle, V, et autres
Publié: (1991)